Nuvas, LLC

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $200K
First Award Date 09/01/98
Most Recent Award Date 03/01/00

Key Personnel

Last Name Name Awards Contact
Dickinson Craig D Dickinson 1
Donate Fernando Donate 2
Houston L L Houston 2

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/00 - 02/28/01

The use of STVTs is a novel approach to eradicating cancer. NuVas's hypothesis is that STVTs cause a thromboetical occlusion of the tumor vessels, whereby nutrients and oxygen are prevented from reaching the dependent tumor cells resulting in ischemic apoptosis and infarctive necrosis of the tumor. To better evaluate the vascular effects the STV...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/04/00 - 01/31/01

Selective Tumor Vascular Targeting Agents (STVTs) are being produced by NuVas and tested in animal models to treat solid tumors. STVTs incorporate modifications to tissue factor (TF) that confer the ability to selectively initiate thrombosis in the tumor microvascular system. Thrombosis blocks the ability of the tumor mass to receive nutrients a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/06/99 - 04/05/00

The distribution of phosphatidylserine (PS) in the cell surface membrane is different between normal and neoplastic tissues. We will use this feature in designing a new family of STVTs (Selective Tumor Vascular Thrombogens) that for two reasons will increase their selectivity and efficacy: (i) PS is preferentially exposed on the outer leaf of th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/20/99 - 03/19/00

STVTs (Selective Tumor Vascular Thrombogens) are (i) engineered to selectively initiate the thrombogenic cascade only on tumor associated vascular endothelium, (ii) incorporate modifications to the structure human tissue factor (TF), which acts as a cofactor for factor VIIA, that have been shown to increase the safety and decrease the toxicity o...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 02/28/99

Selective Tumor Vascular Thrombogens (STVT) will be developed to selectively occlude the vascular bed within solid tumors. STVTs are based on modification of tissue factor and are designed to react transiently as sites within the tumor vascular system to cause the formation of thrombi th...